Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.BO)
INR 208.85
(3.37%)
INR 208.85
(3.37%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 652.59 Million INR | -54.5% |
| 2022 | 1.43 Billion INR | 11.8% |
| 2021 | 1.28 Billion INR | 19.9% |
| 2020 | 1.07 Billion INR | 4.59% |
| 2019 | 1.02 Billion INR | 8.97% |
| 2018 | 938.93 Million INR | 43.92% |
| 2017 | 652.38 Million INR | -22.84% |
| 2016 | 845.46 Million INR | 0.22% |
| 2015 | 843.64 Million INR | 21.44% |
| 2014 | 694.68 Million INR | -12.23% |
| 2013 | 791.44 Million INR | -1.44% |
| 2012 | 803.02 Million INR | -12.68% |
| 2011 | 919.68 Million INR | 17.98% |
| 2010 | 779.54 Million INR | 21.63% |
| 2009 | 640.91 Million INR | 11.86% |
| 2008 | 572.94 Million INR | -2.54% |
| 2007 | 587.88 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 208.99 Million INR | 78.64% |
| 2024 Q2 | 483.31 Million INR | 30.1% |
| 2023 Q1 | 378.64 Million INR | 18.76% |
| 2023 Q2 | 369.2 Million INR | -2.49% |
| 2023 Q3 | 274.93 Million INR | -25.53% |
| 2023 FY | 652.59 Million INR | -54.5% |
| 2023 Q4 | 116.99 Million INR | -57.45% |
| 2022 Q3 | 370.04 Million INR | -5.74% |
| 2022 Q1 | 344.06 Million INR | 23.58% |
| 2022 FY | 1.43 Billion INR | 11.8% |
| 2022 Q4 | 318.82 Million INR | -13.84% |
| 2022 Q2 | 392.56 Million INR | 14.1% |
| 2021 Q4 | 278.41 Million INR | -14.96% |
| 2021 FY | 1.28 Billion INR | 19.9% |
| 2021 Q3 | 327.4 Million INR | -9.01% |
| 2021 Q2 | 359.8 Million INR | 7.63% |
| 2021 Q1 | 334.28 Million INR | 21.29% |
| 2020 FY | 1.07 Billion INR | 4.59% |
| 2020 Q3 | 318.16 Million INR | 11.8% |
| 2020 Q2 | 284.58 Million INR | 48.95% |
| 2020 Q1 | 191.05 Million INR | -11.75% |
| 2020 Q4 | 275.61 Million INR | -13.38% |
| 2019 Q4 | 216.49 Million INR | -22.75% |
| 2019 FY | 1.02 Billion INR | 8.97% |
| 2019 Q1 | 267.43 Million INR | 9.4% |
| 2019 Q3 | 280.25 Million INR | 8.13% |
| 2019 Q2 | 259.18 Million INR | -3.08% |
| 2018 Q1 | 210.51 Million INR | -1.65% |
| 2018 Q2 | 244.67 Million INR | 16.23% |
| 2018 Q3 | 239.28 Million INR | -2.21% |
| 2018 Q4 | 244.46 Million INR | 2.17% |
| 2018 FY | 938.93 Million INR | 43.92% |
| 2017 Q1 | 128.75 Million INR | -37.71% |
| 2017 Q4 | 214.04 Million INR | 20.6% |
| 2017 Q3 | 177.48 Million INR | 32.51% |
| 2017 Q2 | 133.94 Million INR | 4.03% |
| 2017 FY | 652.38 Million INR | -22.84% |
| 2016 Q1 | 238.45 Million INR | -3.2% |
| 2016 FY | 845.46 Million INR | 0.22% |
| 2016 Q2 | 231.41 Million INR | -2.95% |
| 2016 Q3 | 172.63 Million INR | -25.4% |
| 2016 Q4 | 206.69 Million INR | 19.73% |
| 2015 FY | 843.64 Million INR | 21.44% |
| 2015 Q4 | 246.34 Million INR | 12.13% |
| 2015 Q3 | 219.68 Million INR | 9.19% |
| 2015 Q2 | 201.19 Million INR | 14.04% |
| 2015 Q1 | 176.43 Million INR | 10.05% |
| 2014 Q3 | 167.34 Million INR | -7.8% |
| 2014 Q2 | 181.49 Million INR | -2.17% |
| 2014 Q1 | 185.52 Million INR | -24.42% |
| 2014 FY | 694.68 Million INR | -12.23% |
| 2014 Q4 | 160.31 Million INR | -4.2% |
| 2013 Q1 | 169.17 Million INR | 1.52% |
| 2013 Q2 | 189.41 Million INR | 11.97% |
| 2013 Q4 | 245.46 Million INR | 30.98% |
| 2013 Q3 | 187.4 Million INR | -1.06% |
| 2013 FY | 791.44 Million INR | -1.44% |
| 2012 Q1 | 197.86 Million INR | -11.37% |
| 2012 Q2 | 210 Million INR | 6.14% |
| 2012 Q3 | 228.53 Million INR | 8.82% |
| 2012 Q4 | 166.62 Million INR | -27.09% |
| 2012 FY | 803.02 Million INR | -12.68% |
| 2011 FY | 919.68 Million INR | 17.98% |
| 2011 Q3 | 245.28 Million INR | -0.93% |
| 2011 Q2 | 247.6 Million INR | 0.0% |
| 2011 Q4 | 223.23 Million INR | -8.99% |
| 2010 FY | 779.54 Million INR | 21.63% |
| 2009 FY | 640.91 Million INR | 11.86% |
| 2008 FY | 572.94 Million INR | -2.54% |
| 2007 FY | 587.88 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 97.563% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 99.578% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 94.751% |
| Granules India Limited | 16.79 Billion INR | 96.115% |
| Indoco Remedies Limited | 6.04 Billion INR | 89.198% |
| Achyut Healthcare Limited | 4.86 Million INR | -13325.015% |
| Ajanta Pharma Limited | 21.06 Billion INR | 96.902% |
| Alkem Laboratories Limited | 52.29 Billion INR | 98.752% |
| Alpa Laboratories Limited | 188.89 Million INR | -245.478% |
| Brooks Laboratories Limited | 65.62 Million INR | -894.499% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 89.513% |
| Bajaj HealthCare Limited | 1.47 Billion INR | 55.661% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 82.341% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 99.601% |
| Eris Lifesciences Limited | 10.42 Billion INR | 93.741% |
| FDC Limited | 8.33 Billion INR | 92.17% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 99.059% |
| Gufic Biosciences Limited | 4.16 Billion INR | 84.342% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 89.465% |
| Ipca Laboratories Limited | 29.8 Billion INR | 97.811% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -238.608% |
| Lasa Supergenerics Limited | 121.02 Million INR | -439.197% |
| Laurus Labs Limited | 24.62 Billion INR | 97.349% |
| Lupin Limited | 123.71 Billion INR | 99.473% |
| Mankind Pharma Limited | 44.52 Billion INR | 98.534% |
| Medicamen Biotech Limited | 495.49 Million INR | -31.705% |
| Medico Remedies Limited | 262.14 Million INR | -148.943% |
| Megasoft Limited | 342.07 Million INR | -90.776% |
| NATCO Pharma Limited | 25.73 Billion INR | 97.464% |
| Piramal Pharma Limited | 24.47 Billion INR | 97.333% |
| RPG Life Sciences Limited | 2.48 Billion INR | 73.718% |
| Sigachi Industries Limited | 2 Billion INR | 67.408% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.748% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 84.173% |
| Syncom Formulations (India) Limited | 942.39 Million INR | 30.752% |
| Unichem Laboratories Limited | 4.86 Billion INR | 86.586% |
| Wanbury Limited | 1.73 Billion INR | 62.292% |
| Windlas Biotech Limited | 1.33 Billion INR | 51.256% |
| ZIM Laboratories Limited | 1.26 Billion INR | 48.489% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 99.479% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 208.331% |
| Divi's Laboratories Limited | 32.44 Billion INR | 97.988% |
| Hester Biosciences Limited | 1.27 Billion INR | 48.762% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 88.712% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | 58.074% |
| Bal Pharma Limited | 770.19 Million INR | 15.27% |
| Strides Pharma Science Limited | 14.38 Billion INR | 95.464% |
| Venus Remedies Limited | 2.18 Billion INR | 70.1% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 88.809% |
| Nectar Lifesciences Limited | 2.97 Billion INR | 78.043% |
| Shilpa Medicare Limited | 3.54 Billion INR | 81.601% |
| Aarti Drugs Limited | 8.31 Billion INR | 92.153% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 85.754% |
| Suven Life Sciences Limited | -200.79 Million INR | 425.0% |
| Ind-Swift Limited | 2.17 Billion INR | 69.962% |
| Valiant Laboratories Limited | -60.66 Million INR | 1175.745% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 97.125% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | 24.223% |
| Themis Medicare Limited | 1.5 Billion INR | 56.607% |
| Hikal Limited | 3.14 Billion INR | 79.237% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 98.604% |
| Sequent Scientific Limited | 2.97 Billion INR | 78.092% |
| Novartis India Limited | 1.32 Billion INR | 50.818% |
| Wockhardt Limited | 16.24 Billion INR | 95.982% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 96.678% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -4376.018% |
| Neuland Laboratories Limited | 8.24 Billion INR | 92.088% |
| Morepen Laboratories Limited | 6.16 Billion INR | 89.408% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -5.176% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | 7.251% |